Literature DB >> 27489514

Influence of the contrast agents on treatment planning dose calculations of prostate and rectal cancers.

Sahel Heydarheydari1, Negin Farshchian2, Abbas Haghparast1.   

Abstract

AIM: The aim of the present study is to quantify differences in dose calculations caused by using CA and determine if the resulting differences are clinically significant.
BACKGROUND: The influence of contrast agents (CA) on radiation dose calculations must be taken into account in treatment planning.
MATERIALS AND METHODS: Eleven patients with pelvic cancers were included in this study and two sets of CTs were taken for each patient (without and with CA) in the same position and coordinates. Both sets of images were transferred to the DosiSoft ISOgray treatment planning system for contouring and calculating the dose distribution and monitor units (MUs) with Collapsed Cone and Superposition algorithms, respectively. All plans were generated on pre-contrast CT and subsequently copied to the post-contrast CT. Radiation dose calculations from the two sets of CTs were compared using a paired sample t-test.
RESULTS: The results showed a statistically insignificant difference between pre- and post-contrast CT treatment plans for target volume and OARs (p > 0.05), except bladder organ in the prostate region (p < 0.05) but the relative mean dose and MU differences were less than 2% in any patient for 18 MV photon beam.
CONCLUSIONS: Treatment planning on contrasted images generally showed a lower radiation dose to both target volume and OARs than plans on non-contrasted images. The results of this research showed that the small radiation dose differences between the plans for the CT scans with and without CA seem to be clinically insignificant; therefore, contrast-enhanced CT can be used for both target delineation and treatment planning of prostate and rectal cancers.

Entities:  

Keywords:  CT simulation; Contrast agent; Prostate and rectal cancers; Radiotherapy; Treatment planning

Year:  2016        PMID: 27489514      PMCID: PMC4949738          DOI: 10.1016/j.rpor.2016.04.004

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  13 in total

1.  Applications of simulator computed tomography number for photon dose calculations during radiotherapy treatment planning.

Authors:  J C Chu; B Ni; R Kriz; V Amod Saxena
Journal:  Radiother Oncol       Date:  2000-04       Impact factor: 6.280

2.  Influence of the type of imaging on the delineation process during the treatment planning.

Authors:  Weronika Jackowiak; Bartosz Bąk; Anna Kowalik; Adam Ryczkowski; Małgorzata Skórska; Małgorzata Paszek-Widzińska
Journal:  Rep Pract Oncol Radiother       Date:  2015-06-18

3.  Effect of intravenous contrast on treatment planning system dose calculations in the lung.

Authors:  J Lees; L Holloway; M Fuller; D Forstner
Journal:  Australas Phys Eng Sci Med       Date:  2005-09       Impact factor: 1.430

4.  Influence of the intravenous contrast media on treatment planning dose calculations of lower esophageal and rectal cancers.

Authors:  Jabbari Nasrollah; Molazadeh Mikaeil; Esnaashari Omid; Seyed Siahi Mojtaba; Zeinali Ahad
Journal:  J Cancer Res Ther       Date:  2014 Jan-Mar       Impact factor: 1.805

5.  Clustering asian and north african countries according to trend of colon and rectum cancer mortality rates: an application of growth mixture models.

Authors:  Farid Zayeri; Ali Sheidaei; Anita Mansouri
Journal:  Asian Pac J Cancer Prev       Date:  2015

6.  Effect of contrast media on megavoltage photon beam dosimetry.

Authors:  Ashley W Rankine; Peter J Lanzon; Nigel A Spry
Journal:  Med Dosim       Date:  2008       Impact factor: 1.482

7.  Influence of iodine contrast agent on the range of ion beams for radiotherapy.

Authors:  Hansjörg Wertz; Oliver Jäkel
Journal:  Med Phys       Date:  2004-04       Impact factor: 4.071

8.  Effect of CT contrast on volumetric arc therapy planning (RapidArc and helical tomotherapy) for head and neck cancer.

Authors:  Alan J Liu; Nayana Vora; Steve Suh; An Liu; Timothy E Schultheiss; Jeffrey Y C Wong
Journal:  Med Dosim       Date:  2014-09-18       Impact factor: 1.482

Review 9.  Epidemiology of prostate cancer in the Asia-Pacific region.

Authors:  Peter D Baade; Danny R Youlden; Susanna M Cramb; Jeff Dunn; Robert A Gardiner
Journal:  Prostate Int       Date:  2013-06-30

10.  Dosimetric effect of CT contrast agent in CyberKnife treatment plans.

Authors:  Hee Jung Kim; Ah Ram Chang; Yang-Kyun Park; Sung-Joon Ye
Journal:  Radiat Oncol       Date:  2013-10-18       Impact factor: 3.481

View more
  5 in total

1.  Dosimetric impact of contrast-enhanced 4d computed tomography for stereotactic body radiation therapy of hepatocelluar carcinoma.

Authors:  Rose Kamal; Deepak Thaper; Rishabh Kumar; Gaganpreet Singh; Hanuman P Yadav; Arun S Oinam; Vivek Kumar; Hitesh Sharma
Journal:  Rep Pract Oncol Radiother       Date:  2021-08-12

2.  Effect of contrast medium on treatment modalities planned with different photon beam energies: a planning study.

Authors:  Manindra Bhushan; Deepak Tripathi; Girigesh Yadav; Lalit Kumar; Abhinav Dewan; Sarthak Tandon; Gourav Kumar; Inderjit Kaur Wahi; Munish Gairola
Journal:  Rep Pract Oncol Radiother       Date:  2021-09-30

3.  Influence of Using a Contrast-Enhanced CT Image as the Primary Image on CyberKnife Brain Radiosurgery Treatment Plans.

Authors:  Jianping Zhang; Lin Wang; Benhua Xu; Miaoyun Huang; Yuangui Chen; Xiaobo Li
Journal:  Front Oncol       Date:  2021-09-16       Impact factor: 6.244

4.  Segmentation of the prostate, its zones, anterior fibromuscular stroma, and urethra on the MRIs and multimodality image fusion using U-Net model.

Authors:  Seyed Masoud Rezaeijo; Shabnam Jafarpoor Nesheli; Mehdi Fatan Serj; Mohammad Javad Tahmasebi Birgani
Journal:  Quant Imaging Med Surg       Date:  2022-10

5.  Thyroid function following radiation therapy in breast cancer patients: risk of radiation-induced hypothyroidism.

Authors:  Negin Farshchian; Nasrin Amirifard; Mohammad Hosein Saiedian Azar; Sahel Heydarheydari; Nazanin Farshchian; Abbas Haghparast
Journal:  Rep Pract Oncol Radiother       Date:  2022-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.